News Release

Conceptual model identifies factors to mitigate risk for opioid misuse during cancer care

New framework distinguishes between malleable and unmalleable factors, as well as pre- and post-diagnosis factors, to guide screening and management of "chemical coping" with opioids

Peer-Reviewed Publication

Wolters Kluwer Health

November 8, 2023 — Among cancer patients, psychological distress and accessibility of opioids often lead to chemical coping, a middle ground between addiction and proper adherence to a medication regimen. Chemical coping can diminish quality of life and interfere with pain and symptom management, as well as predispose individuals to developing substance use disorder. The findings are reported in the Harvard Review of Psychiatry (HRP), part of the Lippincott portfolio from Wolters Kluwer

Miryam Yusufov, Ph.D., a psychologist in the Department of Psychosocial Oncology and Palliative Care at the Dana-Farber Cancer Institute, a Harvard Medical School teaching hospital in Boston, and colleagues have developed the first conceptual model that integrates the risk factors that initiate and maintain chemical coping with opioids during cancer care. "This model will help care teams triage factors that require monitoring and potential risk mitigation . . . as well as those that require behavioral intervention," the research team notes.  

Predisposing risk factors identified in four overlapping domains 

Based on a search of medical literature in PubMed and MEDLINE, the team found that risk factors and treatment targets for chemical coping in cancer can be organized according to whether they are historical or current and whether they are malleable (amenable to intervention) or unmalleable. The researchers describe the evidence base for each risk factor, some of which fall into multiple domains: 

  • Historical and malleable factors: Depression, anxiety, posttraumatic stress disorder, and other psychological diagnoses; intolerance of distress 

  • Current and malleable factors: Chronic pain, psychological diagnoses, deficit in coping skills, opioid availability 

  • Historical and unmalleable factors: Family history of substance use disorder, including alcohol use disorder; personal history of substance use disorder; history of sexual victimization; childhood abuse  

  • Current and unmalleable factor: Age 16 to 45 

"Therefore, patients with no misuse behaviors are still at risk for chemical coping based on these preexisting risk factors and long-term opioid therapy," the authors say. 

Implications for clinical practice: universal screening, patient education, and mental health care 

Dr. Yusufov and her colleagues recommend screening all patients for risk of chemical coping before initiating opioid therapy. They point out that "it is less stigmatizing to address chemical coping risk than active misuse of opioids." For example, the Opioid Risk Tool (ORT) addresses family and/or personal history of substance use, history of sexual abuse/violence, and psychological disorders.  

Given the recent upward trend in opioid-related hospitalizations among patients with cancer, the authors suggest clinicians may mitigate overdoses and deaths with patient education on naloxone and medication return policies upon therapy completion or regimen changes. 

Finally, the proposed model can aid in selecting components for behavioral interventions and help clinicians determine when to refer patients to psychosocial support resources. This approach can maximize cost-effectiveness while minimizing risk. "For example, if a patient presents with predominantly malleable factors, they may be an appropriate candidate for psychosocial support," Dr. Yusufov's team says. "If a patient presents with predominantly unmalleable factors, however, they may be a more appropriate candidate for continued monitoring throughout opioid therapy." 

Read Article [ Toward a Psychological Model of Chemical Coping with Opioids in Cancer Care ] 

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit and follow us on LinkedIn and Twitter @WKHealth


About HRP 

Harvard Review of Psychiatry is the authoritative source for scholarly reviews and perspectives on a diverse range of important topics in psychiatry. Founded by the Harvard Medical School Department of Psychiatry, the journal is peer-reviewed and not industry-sponsored. It is affiliated with all of the Departments of Psychiatry at the Harvard teaching hospitals. 

Articles encompass all major issues in contemporary psychiatry, including (but not limited to) neuroscience, psychopharmacology, psychotherapy, history of psychiatry, and ethics. In addition to scholarly reviews, perspectives articles, and columns, the journal includes a Clinical Challenge section that presents a case followed by discussion and debate from a panel of experts. 

About Wolters Kluwer  

Wolters Kluwer (EURONEXT: WKL) is a global leader in professional information, software solutions, and services for the healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.  

Wolters Kluwer reported 2022 annual revenues of €5.5 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,900 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. 

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.